Cancer Risks Diagnostic Procedures: Interpret Wisely
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events - including heart attack, stroke, and cardiovascular death - in patients with...
- The SELECT trial followed participants for an average of 3.4 years.
- The study population consisted of adults with obesity (BMI of 30 or higher) and established cardiovascular disease, such as a prior heart attack or stroke.
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events – including heart attack, stroke, and cardiovascular death - in patients with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The study,involving over 17,600 participants,initially aimed to determine if semaglutide could reduce the risk of these events,but the results showed a statistically significant,though modest,increase in risk within the treatment group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Key Findings and Data
The SELECT trial followed participants for an average of 3.4 years. The primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 6.5% of the semaglutide group versus 5.8% of the placebo group, representing a hazard ratio of 1.13. While this difference is statistically significant,it’s vital to note the absolute risk increase was relatively small. Further analysis revealed increases in both cardiovascular death and hospitalization for heart failure.
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| Cardiovascular Death, MI, or Stroke | 6.5 | 5.8 | 1.13 |
| Cardiovascular Death | 2.6 | 1.8 | 1.48 |
| Hospitalization for Heart Failure | 2.2 | 1.7 | 1.31 |
Who is Affected? Understanding the Patient Population
The study population consisted of adults with obesity (BMI of 30 or higher) and established cardiovascular disease, such as a prior heart attack or stroke. Critically, participants were *already* at increased cardiovascular risk before entering the trial. the findings do not necessarily apply to individuals using semaglutide for weight loss who do not have pre-existing heart conditions. However, the results highlight the need for careful patient selection and monitoring, particularly in those with known cardiovascular vulnerabilities.
What Does This Mean? Implications for Clinical Practise
These findings necessitate a reevaluation of the risk-benefit profile of semaglutide in patients with established cardiovascular disease. While semaglutide remains an effective weight loss medication, clinicians must now weigh the potential cardiovascular risks against the benefits, especially when prescribing it to high-risk individuals. A more individualized approach to treatment, considering a patient’s complete medical history and cardiovascular risk factors, is crucial.
Timeline of Events
- November 2023: Results of the SELECT trial are presented at the American Heart Association Scientific Sessions.
- Ongoing: Further analysis of the SELECT